APPLICATION
ANDA218851
TYPE
ANDA
ORIGINAL APPROVAL
2026-03-05
LATEST ACTION
2026-03-05
ROUTE
INTRAVENOUS
DOSAGE FORM
EMULSION
MARKETING STATUS
Discontinued
Products
APREPITANTDiscontinued
APREPITANT 32MG/4.4ML (7.2MG/ML) · EMULSION · INTRAVENOUS
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.